Lysogene has appointed Kimberley S. Gannon, PhD, as its Chief Scientific Officer. Dr. Gannon brings over 15 years of industry experience in CNS research and development at major pharmaceutical firms and early stage biotech companies to strengthen and accelerate Lysogene’s development programs in Mucopolysaccharidosis Type A (also known as Sanfilippo A) and GM1 Gangliosidosis. Dr. Gannon will be based in Lysogene’s U.S. office in Cambridge, Mass., and report directly to CEO Karen Aiach. Prior to joining Lysogene, Dr. Gannon was Senior Vice President of Preclinical Research and Development at NeuroPhage Pharmaceuticals Inc., where she directed preclinical research and drug development activities.